Market Research Cystic Fibrosis Therapeutics Market Analysis 2018

CF is a genetic disorder that mostly affects the lungs and sometimes other parts of the body such as the
liver, pancreas, intestines, and the kidneys. The disease is inherited in an autosomal recessive manner. It
is due to mutations caused in both the copies of the gene for the CFTR protein.
MIR's analysts forecast the global cystic fibrosis therapeutics market to grow at a CAGR of 17.28% during
the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the global cystic fibrosis
therapeutics market for 2018-2022. To calculate the market size, the report presents a detailed picture
of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA
MIR's report, Global Cystic Fibrosis Therapeutics Market 2018-2022, has been prepared based on an in-
depth market analysis with inputs from industry experts. The report covers the market landscape and its
growth prospects over the coming years. The report also includes a discussion of the key vendors
operating in this market.
Get sample copy of this research report at
https://www.marketinsightsreports.com/reports/0227267986/global-cystic-fibrosis-therapeutics-
market-2018-2022/inquiry
Key vendors
- AbbVie
- Gilead
- F. Hoffmann-La Roche
- Vertex Pharmaceuticals
Market driver
- Improved diagnostic technologies
- For a full, detailed list, view our report
Market challenge
- Drug discontinuation
- For a full, detailed list, view our report
Market trend
- Strategic collaborations
- For a full, detailed list, view our report
Key questions answered in this report
- What will the market size be in 2022 and what will the growth rate be?